The Readout Loud

This podcast discusses the ongoing problem of surprise ambulance bills in the US. It highlights the financial burden on patients and the difficulty in finding a fair solution. Personal stories are shared to emphasize the high costs and frustration faced by patients. Different approaches taken by states and the need for a public reckoning in emergency services are explored. The potential consequences of congressional inaction are also discussed, but there is a glimmer of hope with one person receiving a zero-dollar bill due to an insurance error.

This podcast explores the scientific backstory of radiopharmaceuticals, Eli Lilly's new obesity drug, a biotech implosion, and shareholder activism. They also discuss the approval and pricing of Lilly's weight loss drug, upcoming cardiovascular outcome study for Novo Nordisk's WeGoV, and updates in the pharmaceutical industry. Additionally, they delve into the history of the radiopharmaceutical Zevelin and a bittersweet day for IDEC and Zevelin employees during an FDA advisory panel meeting.

Biotech consultant Frank David explains subgroup analyses and how they can be misleading. The podcast also discusses the future of Sarepta and the retirement of a biotech stalwart.

The podcast discusses the highlights of a recent oncology conference, including advancements in cancer-treating technology. It also covers the future of Alzheimer's disease treatment, a multibillion-dollar biotech deal, and the rise of biotech venture capital. The hosts explore the incredible math behind a biotech investment that turned $50 million into $5 billion. They also discuss the challenges faced by the biotech industry, recent developments in Alzheimer's treatment, and advancements in antibody-drug conjugates for cancer treatment.

Live from the 2023 STAT Summit, the hosts discuss genome editing milestones, twists in ALS treatments, and the polarizing process of pronouncing words in biotech. They also explore the potential impact of in vivo gene editing therapy, debates over pronunciation of acronyms and drug names, and the future of neurodegenerative diseases research.

The podcast discusses Bristol Myers Squibb's acquisition of Mirati Therapeutics, the rejection of a treatment by Al Nylon, the impact of GLP-1 drugs on the Nash treatment market, and advancements in genetic engineering using CRISPR technology in animals.

This podcast features Katalin Karikó and Drew Weissman, winners of the Nobel Prize for medicine. They discuss the journey of mRNA technology, challenges in developing an HIV vaccine, and the shortcomings of the Nobel Prize recognition system.

Chemist Svetlana Mojsov's vital role in the discovery of GLP-1 is explored, highlighting patent disputes and challenges faced by women in science. The FDA hearing on BrainStorm's ALS treatment and the state of biotech stocks are also discussed, emphasizing the need for more inclusive recognition in the scientific community.

The podcast explores the promise of artificial wombs and the ethical challenges of developing them. They also discuss the controversial case of a potential ALS medicine and the upcoming FDA meeting. Additionally, they delve into the financial constraints on launching confirmatory studies and the progress in developing artificial wombs for premature babies.

Helen Branswell discusses the state of the pandemic and rollout of booster shots for Covid-19. They also talk about an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.